Abstract: In multiple sclerosis (MS) the gold standard for the diagnosis and prognosis is, up to now, the use of magnetic resonance imaging markers. No alternative simpler assays proven of use, except for cerebrospinal fluid analysis, have been provided in MS diagnosis. Therefore, there is a need to develop non-invasive, sensitive, simple new techniques for the clinical routine. Herein we present the evaluation of the feasibility of a glycopeptide-based biosensor to detect MS specific antibodies in sera using the surface plasmon resonance technology. The previously described glycopeptide antigen CSF114(Glc) has been immobilized on a gold sensor chip and the method has been optimized for real-time specific autoantibody detection directly in sera. A population of 60 healthy blood donors and 61 multiple sclerosis patients has been screened. The receiver operating characteristic (ROC)-based analysis has established the optimal diagnostic cut-off value for the method obtaining a sensitivity of 36% and a specificity of 95%. Sample sera have been also screened with a previously validated ELISA.
Keywords: multiple sclerosis; surface plasmon resonance; serodiagnosis; biacore; immunoassay; glycopeptide CSF114(Glc)
Export to BibTeX
MDPI and ACS Style
Real-Fernández, F.; Passalacqua, I.; Peroni, E.; Chelli, M.; Lolli, F.; Papini, A.M.; Rovero, P. Glycopeptide-Based Antibody Detection in Multiple Sclerosis by Surface Plasmon Resonance. Sensors 2012, 12, 5596-5607.
Real-Fernández F, Passalacqua I, Peroni E, Chelli M, Lolli F, Papini AM, Rovero P. Glycopeptide-Based Antibody Detection in Multiple Sclerosis by Surface Plasmon Resonance. Sensors. 2012; 12(5):5596-5607.
Real-Fernández, Feliciana; Passalacqua, Irene; Peroni, Elisa; Chelli, Mario; Lolli, Francesco; Papini, Anna Maria; Rovero, Paolo. 2012. "Glycopeptide-Based Antibody Detection in Multiple Sclerosis by Surface Plasmon Resonance." Sensors 12, no. 5: 5596-5607.